000			02734nab a22002777a 4500
008			180226b2018 xxu||||| |||| 00| 0 eng d
100			_aNoronha V
245			_aCarboplatin-based concurrent chemoradiation therapy in locally advanced head and neck cancer patients who are unfit for cisplatin therapy
260			_c2017
300			_a
500			_aAddress for corresponding author : kumarprabhashtmh@gmail.com
520			_aAbstract BACKGROUND: Cisplatin-based chemoradiation (CTRT) is the standard of care in locally advanced head and neck cancers. Limited treatment options are available in patients unfit for cisplatin. AIMS: This audit was carried out to study the toxicities, tolerance, and outcomes of carboplatin-based CTRT in patients who are not eligible for cisplatin. MATERIALS AND METHODS: A total of 63 locally advanced head and neck cancer patients treated between January 2011 and October 2015 were administered carboplatin-based CTRT. The dose of carboplatin was equivalent to area under the curve equivalent to 2 administered once a week for a maximum of 7 cycles. Toxicity was coded as per the CTCAE version 4.03. SPSS software version 16 was used for statistical analysis. STATISTICAL ANALYSIS: Descriptive statistics was performed. Progression-free survival (PFS) and overall survival (OS) were estimated by Kaplan-Meier survival analysis. Cox proportional hazard model was used for identifying factors affecting PFS and OS. RESULTS: The reasons for patients being unfit for cisplatin were low serum creatinine clearance in 41 (65.07%), sensorineural hearing loss in 18 (28.57%), uncontrolled medical comorbidities in 3 (4.76%), and old age in 1 patient (1.6%). 53 patients (84.1%) completed planned radiotherapy. The median number of chemotherapy cycles administered was 6. Grade 3-4 toxicities were seen in 32 patients (50.8%). The median OS and PFS were 28 months (95% confidence interval [CI]: 20.9-34.6 months) and 17 months (95% CI: 08.2-25.7 months), respectively. Age was the only factor significantly affecting OS and PFS. CONCLUSION: Carboplatin-based CTRT is well tolerated in patients unfit for cisplatin and seems to have superior outcomes than those reported in radical radiotherapy studies.
650			_aCarboplatin
650			_aChemoradiation
650			_aCisplatin
650			_aHead and neck cancers
650			_aUnfit
700			_aSharma V
700			_aJoshi A
700			_aPatil VM
700			_aLaskar SG
700			_aPrabhash K _eCorresponding author
773			_078063 _aIndian Journal of Cancer _dMumbai : Medknow Publications, 2017 _gVol. 54, no. 2, p. 453-457 _x0019-509X
906			_aMED ONC _bTMC _c29469077 _eJA _fNA _hTMH
942			_cAR
999			_c82836 _d82836